Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.37 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.37 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.37 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403795 | 0.76 | HDAC1 (0.46) | MMP8ANPEPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1109398 | 0.75 | HDAC1 (0.49) | SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL404999 | 0.75 | BACE1 (0.40) | ANPEP | |
| SCHEMBL404744 | 0.74 | MEP1B (0.49) | ANPEP | |
| SCHEMBL1109283 | 0.74 | HDAC1 (0.49) | ANPEPNPC1RAB9A | |
| SCHEMBL404713 | 0.73 | ANPEP (0.38) | ANPEPNPC1RAB9A | |
| SCHEMBL401475 | 0.71 | TAS1R3 (0.55) | ANPEPNPC1RAB9A | |
| SCHEMBL4921436 | 0.68 | MMP13 (0.58) | MMP8 | |
| SCHEMBL4921444 | 0.68 | MMP13 (0.58) | MMP8 | |
| SCHEMBL7463584 | 0.68 | ANPEP (0.54) | ANPEPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | MMP8 108/4885ANPEP 744/4885NPC1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.